IPO registrations (S-1, F-1) · Underwriters
Bryan, Garnier & Co
- Deals
- 10 priced offerings as an underwriter; 9 initial public offerings
- Proceeds of those deals
- $1,739,447,738
- Years
- 2000–2023
- Named in
- 16 prospectuses and registration statements in all, including offerings not yet priced or withdrawn
- Named as
- Bryan, Garnier & Co; Bryan Garnier & Company
Deals by year
| Year | Deals | As lead | Proceeds of deals |
|---|---|---|---|
| 2023 | 1 | 0 | $252,849,220 |
| 2021 | 1 | 0 | $187,062,827 |
| 2019 | 2 | 0 | $285,128,000 |
| 2017 | 1 | 0 | $200,025,000 |
| 2015 | 2 | 0 | $375,525,100 |
| 2014 | 1 | 0 | $57,857,591 |
| 2013 | 1 | 0 | $75,000,000 |
| 2000 | 1 | 0 | $306,000,000 |
Deals 10
| Priced | Company | Role | Price | Range | Shares | Proceeds | Listing | Kind | Syndicate | Prospectus |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023-10-23 | Abivax S.A. | Syndicate | $12.44 | 20,325,500 | $252,849,220 | Nasdaq ABVX | IPO | 4 | 424B4 ↗ | |
| 2021-05-07 | Valneva SE I0 | Syndicate | $26.41 | 7,082,762 | $187,062,827 | Nasdaq VALN | IPO | 5 | 424B4 ↗ | |
| 2019-10-11 | BioNTech SE 2M | Syndicate | $15.00 | 10,000,000 | $150,000,000 | Nasdaq BNTX | IPO | 8 | 424B4 ↗ | |
| 2019-03-27 | Genfit S.A. I0 | Syndicate | $20.32 | 6,650,000 | $135,128,000 | Nasdaq GNFT | IPO | 6 | 424B4 ↗ | |
| 2017-10-25 | Ablynx NV C9 | Syndicate | $17.50 | 11,430,000 | $200,025,000 | Nasdaq ABLX | Offering | 9 | 424B4 ↗ | |
| 2015-06-19 | Celyad Oncology SA C9 | Syndicate | $68.56 | 1,460,000 | $100,097,600 | Nasdaq CYAD | IPO | 5 | 424B4 ↗ | |
| 2015-05-14 | Lakefront Biotherapeutics NV | Syndicate | $42.05 | 6,550,000 | $275,427,500 | Nasdaq GLPG | IPO | 5 | 424B4 ↗ | |
| 2014-10-22 | DBV Technologies S.A. | Syndicate | $21.64 | 2,673,641 | $57,857,591 | Nasdaq DBVT | IPO | 4 | 424B4 ↗ | |
| 2013-10-09 | LDR HOLDING CORP TX | Syndicate | $15.00 | 5,000,000 | $75,000,000 | Nasdaq LDRH | IPO | 6 | 424B1 ↗ | |
| 2000-03-16 | ACTIVCARD SA I0 | Syndicate | $76.50 | 4,000,000 | $306,000,000 | Nasdaq ACTI | IPO | 10 | 424B1 ↗ |
“Offering” is a priced registered offering that the cover page does not describe as an initial public offering: a follow-on, a resale, or a small company’s best-efforts deal.
Works alongside
| Firm | Deals together | Of which that firm led |
|---|---|---|
| Leerink Partners | 4 | 4 |
| Cowen | 3 | 1 |
| J.P. Morgan | 3 | 3 |
| BofA Securities | 2 | 1 |
| Jefferies | 2 | 2 |
| LifeSci Capital | 2 | 0 |
| Morgan Stanley | 2 | 2 |
| Piper Sandler | 2 | 2 |
| UBS | 2 | 2 |
| ADSs Merrill Lynch, Pierce, Fenner & Smith Incorporated | 1 | 0 |
| Baird | 1 | 0 |
| Barclays | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Offering terms are read from the cover pages of the registrant's final prospectus (424B4, 424B1) and its latest registration statement before pricing: the price range, the final price, shares offered, gross proceeds (the cover's total, else price times shares), exchange and ticker, and the underwriters named on the cover and in the underwriting table (loader/s1_terms.py). Underwriter names are normalised, so Goldman, Sachs & Co. of 1999 and Goldman Sachs & Co. LLC of 2024 are one firm.